NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.

NeoGenomics Inc. (NEO), which provides cancer-focused genetic testing and contract research, has agreed to acquire Inivata Limited. Inivata is a commercial-stage liquid biopsy platform provider.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth ...

Management raised full-year 2025 revenue guidance to $747 million-$759 million, reflecting 13%-15% growth. Adjusted EBITDA guidance remains unchanged at $55 million-$58 million. Pathline is projected ...

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 34.1% and a 59.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, marking nine consecutive quarters of double-digit growth. He also announced his retirement effective ...

NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, ...

NeoGenomics (NEO), a Fort Myers-based cancer testing and research lab, surprised Wall Street Monday with higher-than-expected third-quarter revenue and break-even earnings per share. The company ...

FT. MYERS, FL / ACCESSWIRE / March 24, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced ...

The cancer-focused genetic testing service provider upgraded its offerings to provide higher-quality data from the same biological samples. That should keep growth humming along. Another quarter, ...

The Most Attractive Stocks (+2.2%) underperformed the S&P 500 (+4.8%) from December 2, 2021 through January 3, 2022 by 2.6%. The best performing large cap stock gained 11% and the best performing ...